Cannabinomimetic Lipid from a Marine Cyanobacterium

Marcelino Gutiérrez,*,[†,‡] Alban R. Pereira,[†] Hosana M. Debonsi,[†,§] Alessia Ligresti,[⊥] Vincenzo Di Marzo,[⊥] and William H. Gerwick*,[†]

[†]Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States

[‡]Instituto de Investigaciones Científicas y Servicios de Alta Tecnología, Ciudad del Saber, Clayton 0843-01103, Panamá

[§]Departamento de Física e Química, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo 14040903, Brazil

[⊥]Institute of Biomolecular Chemistry, National Research Council, 80078 Pozzuoli, Italy

S *Supporting Information*

ABSTRACT: NMR-guided fractionation of two independent collections of the marine cyanobacteria *Lyngbya majuscula* obtained from Papua New Guinea and *Oscillatoria* sp. collected in Panama led to the isolation of the new lipids serinolamide A (**3**) and propenediester (**4**). Their structures were determined by NMR and MS data analysis. Serinolamide A (**3**) exhibited a moderate agonist effect and selectivity for the CB$_1$ cannabinoid receptor (K_i = 1.3 μM, >5-fold) and represents the newest addition to the known cannabinomimetic natural products of marine origin.

An important development in neuropharmacological research has been the discovery of specific cannabinoid receptors (CB$_1$ and CB$_2$) in central and peripheral mammalian tissues.[1−3] Both receptor subtypes have amino acid sequences characteristic of G-protein-coupled receptors (GPCR).[2,4] CB$_1$ receptors exhibit a widespread distribution in the brain and are responsible for the psychological and anticonvulsive effects produced by marijuana.[3,4] CB$_2$ receptors are most abundant in the immune system, and they appear to be involved in the anti-inflammatory and possibly other therapeutic effects of cannabis.[3−5] Thus, CB$_2$ represents an attractive pharmacological target for developing cannabinoid-based therapeutic agents in the treatment of several human conditions (e.g., cancer, chemotherapy relief, neuropathic pain, neurotrauma, and appetite regulation).[6]

The characterization of the CB$_1$ and CB$_2$ receptors has launched the quest for their corresponding endogenous ligands, which led in 1992 to the isolation of the lipid derivative anandamide (**1**).[2,7] This endogenous metabolite binds to both CB$_1$ and CB$_2$ receptors and is found in nearly all tissues in a wide range of animals.[2] Besides **1**, several other endogenous fatty acid-derived compounds have been reported that are capable of binding one or both of the cannabinoid receptors.[6,8] Among them, 2-arachidonoylglycerol (**2**) is more abundant and efficacious than **1**, but as a monoglyceride, it takes part in several other pathways of lipid metabolism that minimizes its availability for endocannabinoid signaling.[2,9]

Marine organisms in general, and cyanobacteria in particular, have been a rich source of unusual alkyl amides that resemble structurally some aspects of anandamide and other endocannabinoids.[10] Our group has previously reported cannabinomimetic activity for the chlorosulfolipid malhamensilipin A,[10c] as well as the fatty acid-based metabolites grenadadiene[10d] and semiplenamides A, B, and G.[10e]

As part of an ongoing program aimed at characterizing the bioactive natural products of various marine organisms, we investigated the extracts of two independent collections of marine cyanobacteria that shared similar NMR characteristics. The first extract, prepared from a specimen of *Lyngbya majuscula* collected in Papua New Guinea, was fractionated chromatographically to afford the new cannabinoid-active lipid, serinolamide A (**3**), bearing a strong structural similarity to anandamide (**1**). Extracts from this same collection of *L. majuscula* were reported previously to produce the potent cancer cell cytotoxin apratoxin D, a cyclodepsipeptide metabolite.[11] The second extract, derived from a *Oscillatoria* sp. specimen, showed NMR resonances analogous to those of serinolamide A (**3**), and its ^{1}H NMR-guided fractionation led to the discovery of the new cyanobacterial lipid propenediester (**4**). Herein, we report the isolation, structure elucidation, and biological activity of serinolamide A (**3**) and propenediester (**4**), two new endocannabinoid-like lipids isolated from marine cyanobacteria.

1 R = NHCH$_2$CH$_2$OH
2 R = OCH(CH$_2$OH)$_2$

3

4

The marine cyanobacterium *L. majuscula* was collected by hand using scuba from New Ireland in Papua New Guinea. The sample was extracted with CH$_2$Cl$_2$−MeOH (2:1), and 8.8 g of the resulting extract was fractionated by silica gel vacuum-liquid chromatography (VLC) to obtain nine fractions (A−I). Further purification of this material using reversed-phase HPLC yielded 2.9 mg (0.03%) of serinolamide (**3**). HRESITOFMS analysis of **3** showed a pseudomolecular ion [M + H]$^+$ at *m/z* 384.3479 and its sodium adduct [M + Na]$^+$ at *m/z* 406.3295, corresponding with the molecular formula, C$_{23}$H$_{45}$NO$_3$, and indicating that this compound possesses two degrees of unsaturation. IR spectroscopy showed absorptions at 3351 and 1622 cm^{-1}, suggesting the presence of hydroxy and amide-carbonyl groups. The ^{1}H NMR spectrum of **3** showed resonances for three methyl groups, two of which were consistent with being directly attached to oxygen and nitrogen atoms, respectively [δ 3.33 (s, H-23) and 3.01 (s, H-19)] (Table 1). The third methyl group

Table 1. NMR Spectroscopic Data (500 MHz, CDCl$_3$) for Serinolamide A (3)

carbon	δ$_C$, mult.^{a}	δ$_H$, mult. (*J* in Hz)^b	HMBC^c	COSY
1	174.3, C			
2	34.3, CH$_2$	2.40, m	1, 3, 4	3
3	28.1, CH$_2$	2.32, m	1, 2, 4, 5	2, 4
4	128.4, CH	5.43, m	3	3, 5
5	131.6, CH	5.47, m	6	4, 6
6	32.6, CH$_2$	1.96, dd (6.5, 13.5)	4, 5, 7	5
7	29.5, CH$_2$	1.25, m		
8^d	29.2, CH$_2$	1.25, m		
9^d	29.3, CH$_2$	1.25, m		
10^d	29.64, CH$_2$	1.25, m		
11−15^d	29.68, 5 × CH$_2$	1.25, m		
16	31.9, CH$_2$	1.25, m		
17	22.7, CH$_2$	1.28, m	14, 16	18
18	14.1, CH$_3$	0.88, t (6.5)	16, 17	17
19	33.8, CH$_3$	3.01, s	1, 20	
20	57.8, CH	4.39, m	1, 19, 21, 22	21, 22
21	62.3, CH$_2$	3.78, m	20, 22	20
22	71.0, CH$_2$	3.66, dd (7.0, 10.0)	20, 21, 23	20
		3.56, dd (4.5, 10.0)	20, 21, 23	20
23	58.9, CH$_3$	3.33, s		

^{a}Recorded at 125 MHz. ^{b}Recorded at 500 MHz. ^{c}From proton to the indicated carbon. ^{d}Assignments may be interchanged.

at δ 0.88 (t, *J* = 6.5 Hz, H-18) showed a chemical shift and multiplicity typical of a terminal methyl group of a fatty acid chain. Furthermore, resonances for 16 methylenes were observed, some of which were deshielded to shifts corresponding to oxymethylenes [δ 3.78 (m, H-21), 3.66 (dd, *J* = 7.0, 10.0 Hz, H-22a), and 3.56 (dd, *J* = 4.5, 10.0 Hz, H-22b)]. Other methylene groups appeared at high field [δ 2.40 (m,

H-2), 2.32 (m, H-3), 1.96 (m, H-6), and 1.28 (m, H-17)], which, in combination with a 20H signal at δ 1.25 for 10 methylenes and two methine resonances at δ 5.43 (m, H-4) and 5.47 (m, H-5), defined a monounsaturated alkyl chain. The remaining resonance in the spectrum of **3** was a deshielded methine resonance at δ 4.39 (m, H-20) and, by HSQC, corresponded to a nitrogen-bonded methine.

The ^{13}C NMR spectrum of **3** showed resonances for only 19 carbon atoms. However, the carbon at δ 29.7 was of larger intensity, indicating a superposition of several carbon atoms, as is typical for chemically equivalent methylenes in a fatty acid chain. With 23 carbon atoms assigned to **3** by HRMS analysis, the ^{13}C NMR and gHSQC spectra were interpreted to contain three methyl groups, 16 methylenes, three methines, and one quaternary carbon (Table 1).

Overall, analysis of the NMR data of compound **3** (Table 1) allowed the construction of two substructures (Figure 1A).


Figure 1. Assembly of compounds **3** (A) and **4** (B) from their 2D NMR data.

In the first, a prominent singlet at δ 1.25 ppm (20 H) and a triplet at δ 0.88 (3H) suggested the presence of a mostly saturated fatty acid moiety. COSY and HMBC correlations allowed the assignment of the spin system formed by H-2, H-3, H-4, H-5, and H-6 (**I**, Figure 1A), and the *trans*-geometry of the C-4/C-5 double bond was assigned on the basis of the δ$_C$ values of C-3 and C-6, which are typical for allylic methylenes of a *trans* double bond.[12] The group of 10 overlapped methylenes observed at δ 1.25 ppm was localized between C-6 and C-17 on the basis of COSY and HMBC correlations, completing the assignment of substructure **I** (Figure 1A).

The second substructure, **II**, consisted of a dimethyl serinol unit that was elucidated as follows. The spin system formed by H-20, H-21, and H-22 was assigned by COSY and ^{2,3}*J* HMBC correlations. The chemical shifts of carbons C-21 and C-22 were typical for oxygen-bonded methylenes, while the chemical shift of the carbon C-20 indicated that it is attached to nitrogen. Methyl groups at δ 3.01 (H-19) and 3.33 (H-23) were attached to the serinol nitrogen and the oxygen at C-22, respectively, on the basis of diagnostic HMBC correlations, thus completing the assignment of substructure **II**. Substructures **I** and **II** were connected by HMBC correlations observed between the N-Me protons with carbons C-1 and C-20 as well as correlations observed between H-20 and carbons C-1, C-21, and C-22 (Figure 1A).

The absolute configuration at C-20 of the serinol unit was established via chiral derivatization of **3** with (*R*)- and (*S*)-2-(anthracen-9-yl)-2-methoxyacetic acid (9-AMA), according to the methodology reported by Riguera and co-workers for determining the absolute configuration of β-chiral primary alcohols.[13] Examination of $\Delta\delta$ values obtained from the *R*- and *S*-ester derivatives **3a** and **3b** led to an *S*-configuration assigned at C-20. For the natural product **3** the priority rules for the substituents change, and thus, serinolamide (**3**) possesses the *R*-configuration at C-20.


Figure 2. $\Delta\delta^{RS}$ values (ppm, DMSO-d_6) for the 9-AMA esters **3a** and **3b**. The priority order of the substituents at C-20 changes when $R_2 = H$; thus the natural product **3** possesses an *R*-configuration at C-20.

In the case of *Oscillatoria* sp., a black mat of cyanobacterial biomass was collected by hand from Isla Canales de Afuera, Panamá. A similar extraction and fractionation strategy produced nine subfractions (A−I), for which fractions A (1.3 mg) and B (22.0 mg) displayed similar intriguing ^{1}H NMR resonances and LC-MS data to those for compound **3**. Thus, fractions A and B were combined and subjected to further silica gel column chromatography to afford metabolite **4** (6.6 mg, 0.1%).

HRESIMS of **4** yielded an [M + Na]$^+$ peak at *m/z* 417.2978, which when combined with the NMR data (Table 2), was consistent with the molecular formula $C_{24}H_{42}O_4$, possessing four degrees of unsaturation (calcd for $C_{24}H_{42}O_4Na$, 417.2975). Intense IR absorptions at 1746 and 1136 cm^{-1} suggested the presence of double and single carbon−oxygen bonds of an ester functional group. The ^{1}H NMR spectrum of **4** (Table 2) displayed resonances assignable to a deshielded vinylic proton at δ 7.23 and its coupling partner at δ 5.08, a complex multiplet for two deshielded methylenes between δ 4.76 and 4.70, six methylene multiplets at δ 2.43, 2.06, 1.99, 1.81, 1.40, and 1.28, nine isochronous methylenes centered at δ 1.25, a methyl singlet at δ 2.07, and a final methyl triplet at δ 0.88. In agreement with these assignments, the ^{13}C NMR spectrum of **4** showed two sp^2 methine carbons at δ 136.9 and 107.4, a methylene carbon at δ 57.9 (adjacent to oxygen), two methyl resonances at δ 20.9 and 14.1, and a series of 12 methylene carbons ranging from δ 35.8 to 22.4. This spectrum was completed by deshielded quaternary carbonyl-type resonances at δ 170.8 and 170.1, as well as a quaternary sp^2 carbon at δ 148.5 and a sp^2 methylene resonance at δ 109.7. Extensive analysis by 2D NMR methods, including the HSQC, HMBC, and COSY spectra, revealed the planar structure of propenediester (**4**) as described below.

The most prominent resonance in the ^{1}H NMR spectrum of **4** was an apparent singlet centered at δ 1.25, which accounted for a total of 18 protons assigned as methylenes via the HSQC

Table 2. NMR Spectroscopic Data (600 MHz, CDCl$_3$) for Propenediester (4)

carbon	δ_C, mult.^{a}	δ_H, mult. (*J* in Hz)^b	HMBC^c	COSY
1	170.1, C			
2	33.3, CH$_2$	2.43, t (7.4)	1, 3, 4	3, 4
3	22.4, CH$_2$	1.81, tt (7.4, 7.6)	1, 2, 5	2, 4
4	35.1, CH$_2$	2.06, t (7.6)	2, 3, 5, 6, 19	2, 3, 6, 19
5	148.5, C			
6	35.8, CH$_2$	1.99, t (7.6)	5, 7, 19	4, 7, 19
7	27.7, CH$_2$	1.40, tt (6.8, 7.6)	8	6, 8
8	29.7, CH$_2$	1.25, m		7
9−12^d	29.6, 4 × CH$_2$	1.25, m		
13^d	29.5, CH$_2$	1.25, m		
14^d	29.4, CH$_2$	1.25, m		
15^d	29.3, CH$_2$	1.25, m		
16	31.9, CH$_2$	1.25, m		17
17	22.7, CH$_2$	1.28, m	16	16, 18
18	14.1, CH$_3$	0.88, t (7.1)	16, 17	17
19	109.7, CH$_2$	4.73, d (16.6)	4, 6	4, 6
20	136.9, CH	7.23, dt (1.5, 6.5)	1, 21, 22	21, 22
21	107.4, CH	5.08, dt (6.5, 7.1)	20	20, 22
22	57.9, CH$_2$	4.72, dd (1.5, 7.1)	20, 21, 23	20, 21
23	170.8, C			
24	20.9, CH$_3$	2.07, s	23	

^{a}Recorded at 125 MHz. ^{b}Recorded at 600 MHz. ^{c}From proton to the indicated carbon. ^{d}Assignments may be interchanged.

spectrum, and was indicative of a saturated fatty acid chain. COSY data allowed definition of the termini flanking this alkyl chain. At one end an ethyl group was found as revealed by a methyl triplet at δ 0.88 (H-18, *J* = 7.1 Hz, δ_C 14.1) and a methylene multiplet at δ 1.28 (H-17, δ_C 22.7). The other end was composed of a 1,1-disubstituted double bond, as indicated by a deshielded sp^2 methylene group at δ 4.73 (H$_2$-19, apparent d, *J* = 16.6 Hz, δ_C 109.7) and a sp^2 quaternary carbon at δ 148.5 (C-5). The protons for this unusual branching methylene showed both COSY and HMBC correlations with flanking methylenes at δ 1.99 (H-6, apparent t, *J* = 7.6 Hz, δ_C 35.8) and 2.06 (H-4, apparent t, *J* = 7.6 Hz, δ_C 35.1). The former was separated from the C$_9$ saturated alkyl chain mentioned above by an additional methylene at δ 1.40 (H-7, m, δ_C 27.7), whereas the latter methylene was found to comprise a new spin system with methylenes at δ 1.81 (H-3, tt, *J* = 7.4, 7.6 Hz, δ_C 22.4) and 2.43 (H-2, t, *J* = 7.4 Hz, δ_C 33.3). HMBC correlations from H-3 and H-2 were used to situate an ester-type carbonyl (δ 170.1, C-1) at the end of this spin system, thus completing the elucidation of the major portion of compound **4** (fragment **III**, Figure 1B).

A second spin system in **4** contained a polarized vinylic pair at δ 7.23 (H-20, dt, *J* = 1.5, 6.5 Hz, δ_C 136.9) and 5.08 (H-21, dt, *J* = 6.5, 7.1 Hz, δ_C 107.4), followed by a deshielded methylene (adjacent to oxygen) at δ 4.72 (H-22, dd, *J* = 1.5, 7.1 Hz, δ_C 57.9), exhibiting vicinal and allylic coupling with H-21 and H-20, respectively (fragment **IV**). The configuration of the polarized double bond was determined as *Z* on the basis a $^3J_{H20,H21}$ value of 6.5 Hz. A HMBC correlation from H-20 to C-1 enabled substructures **III** and **IV** to be connected. Likewise, a HMBC correlation from H-22 with a carbonyl carbon at δ 170.8 (C-23) was used to join **IV** with **V**, identified as an acetyl group comprising C-23 and the methyl singlet at δ 2.07 (H-24, δ_C 20.9). This completed the structure elucidation

of propenediester (**4**), a compound with a uniquely branched fatty acid chain.

Due to the similarity in structural features of metabolites **3** and **4** to those of known endocannabinoids (e.g., **1** and **2**), these were evaluated for cannabimimetic properties in radio-ligand binding assays specific for human CB_1 and CB_2 receptors. Compound **3** exhibited moderate affinity for the CB_1 cannabinoid receptor with a K_i value of 1.3 μM, whereas **4** was completely inactive (Table 3). More importantly, **3** appears

Table 3. CB_1 and CB_2 Receptor Affinity of Compounds 3 and 4

compound	CB_1 IC_{50} (μM)	CB_2 IC_{50} (μM)
Δ^9-THC[a]	0.0028	0.0095
3	2.3 ± 0.1[b]	>10
4	>10	>10

[a]Positive control. [b]K_i = 1.3 μM.

to be selective for CB_1 (>5-fold). Although other CB_1 agonists (e.g., Δ^9-THC, HU-210, ACEA) exhibit much higher affinity and selectivity over CB_2 receptors, only a handful of marine natural products are reported to show such potency and selectivity for CB_1 receptors.[14] Furthermore, chemical entities exhibiting K_i values in the micromolar range such as **3** potentially can exert cannabimimetic effects in vivo, making them attractive from a therapeutic development perspective. Metabolite **3** was cytotoxic when evaluated in vitro against the H-460 human lung cell line (50 μg/mL, 0% cell survival; 5 μg/mL, 60% cell survival), whereas compound **4** was inactive at all tested concentrations (up to 20 μg/mL). These effects might be ascribed to the potential CB_1 agonist activity of **3**, since CB_1 agonists have been shown to exert cytotoxic effects via either induction of apoptosis or inhibition of proliferation.[15] The lack of cannabinoid-type activity for propenediester (**4**) in these binding assays suggests that moieties containing a hydrogen bond donor at the hydrophilic end of their molecule are required to elicit cannabinoid activity. *N*-Arachidonoyl-L-serine, an endogenous mediator found in mammalian tissues and sharing perhaps a greater chemical similarity with **3** than **1**,[16] was found to be completely inactive in both human CB_1 and CB_2 binding assays (K_i > 10 μM), despite containing a secondary amide group in its chemical structure, and possibly because of the presence of a terminal carboxyl group instead of the methoxy group of **3**.

Biogenetically, the C-1 to C-18 substructure of compounds **3** and **4** is probably derived from a PKS pathway, responsible for the production of fatty acids. The serinol unit in **3** likely originates from serine, which has been reported to be bio-synthesized by cyanobacteria from phosphoglycerate through the phosphorylated pathway.[17] Incorporation of *N*-Me and *O*-Me groups in the serinol residue of compound **3** occurs presumably via SAM-dependent methyltransferases.[18] In the case of compound **4**, its intriguing 1,1-disubstituted double bond branch at C-5 resides at a predicted carbonyl site in the nascent polyketide and, thus, is probably produced by a β-branch mechanism involving an HMG-CoA synthase cassette[19] followed by dehydration to generate the double bond. Although highly speculative, it is tempting to attribute fragment **IV** in **4** to glycerol, which would undergo elimination of its middle substituent (C21) through a more stable secondary inter-mediate (elimination at C-20 or C-22 would involve a primary intermediate).

■ EXPERIMENTAL SECTION

General Experimental Procedures. Optical rotations were measured on a JASCO P-2000 polarimeter, whereas UV data were obtained using a Beckman DU800 spectrophotometer. IR spectra were recorded on a Nicolet 100 FT-IR spectrometer. ^{1}H, ^{13}C, and 2D NMR spectra were collected at a ^{1}H resonance frequency of either 600 MHz (Bruker Avance III DRX600 equipped with a 1.7 mm TCI cryoprobe) or 500 MHz (Varian INOVA 500). Chemical shifts were calibrated internally to the residual signal of the solvent in which the sample was dissolved (CDCl$_3$, δ_H 7.26, δ_C 77.0; DMSO-d_6, δ_H 2.50, δ_C 39.5). High-resolution mass spectra were obtained on a ThermoFinnigan MAT900XL mass spectrometer. HPLC was carried out using a dual Waters 515 pump system equipped with a Waters 996 photodiode array detector. Vacuum and flash chromatographic separations were performed using silica gel type H (10−40 μm, Aldrich) and silica gel 60 (40−63 μm, EMD), respectively. Merck TLC sheets (silica gel 60 F254) were used for analytical TLC (aluminum-supported, layer thickness 200 μm) and preparative TLC (glass-supported, layer thickness 250 μm). All solvents were purchased as HPLC grade. Cytotoxicity to H-460 cells was determined as previously reported.[21]

Cyanobacterial Collections and Taxonomic Identification. The marine cyanobacterium *Lyngbya majuscula* (voucher specimen available from W.H.G. as collection code PNG 5-22-05-3) was collected by scuba at a depth of 15 m from New Ireland, Papua New Guinea, in May 2005 (S 3°49.626′, E 152°26.017′). Specimens of *Oscillatoria* sp. (voucher specimen available from W.H.G. as collection code PAC-17-FEB-10-3) were collected by hand at a depth of 1−1.5 m on flat rocks at Isla Canales de Afuera, Coiba National Park, Republic of Panama, in February 2010 (07°41.723′ N, 81°38.025′ W). The samples were stored in 1:1 EtOH−H$_2$O and frozen at −20 °C prior to extraction. Morphological and molecular characterizations as well as phylogenetic analyses on *L. majuscula* (PNG 5-22-05-3) are described elsewhere.[11] Morphological characterization on *Oscillatoria* sp. was performed using an Olympus IX51 epifluorescent microscope (1000×) equipped with an Olympus U-CMAD3 camera. Morpho-logical comparison and putative taxonomic identification of the cyanobacterial specimen were performed in accordance with modern classification systems.[20] These results were consistent with a phylogenetic analysis of this organism using the 16S rRNA subunit, as detailed elsewhere.[22]

Extraction and Isolation. *L. majuscula* and *Oscillatoria* sp. were extracted separately with 2:1 CH$_2$Cl$_2$−MeOH and concentrated to dryness in vacuo to give 8.8 g and 91.0 mg of crude extract, respectively. Separate VLC prefractionation of the crude extracts using a gradient with 0−100% EtOAc in hexanes followed by 0−100% of MeOH in EtOAc yielded nine fractions (A−I). VLC fraction H from *L. majuscula* eluted with 25% MeOH in EtOAc (1.5 g) and was further fractionated by flash column chromatography on silica gel using a stepwise gradient of MeOH in CH$_2$Cl$_2$ to yield nine sub-fractions (H1−H9). Fraction H2 was purified by reversed-phase HPLC (continuous gradient from 60:40 MeOH−H$_2$O to 100% MeOH in 65 min at 2 mL/min) to give 2.9 mg of serinolamide A (**3**) as a pale yellow oil (0.03%). VLC fractions A (eluted with 100% hexanes, 1.3 mg) and B (eluted with 10% EtOAc in hexanes, 22.0 mg) from *Oscillatoria* sp. were combined according to their ^{1}H NMR, LCMS, and TLC profiles and subjected to ^{1}H NMR-guided fractionation using silica gel column chromatography (10% EtOAc in hexanes) to yield 6.6 mg (0.1%) of propenediester (**4**).

Serinolamide A (3): pale yellow, oil $[\alpha]^{25}_D$ +2.6 (*c* 0.28, CHCl$_3$); IR (film) λ_{max} 3351 (br), 2930, 2853, 1622, 1457, 1404, 1099, 1047 cm^{-1}; ^{1}H and ^{13}C NMR, see Table 1; ESIMS *m/z* 384 (75) $[M + H]^+$, 767 (100) $[2 M + H]^+$; HRESITOFMS *m/z* $[M + H]^+$ 384.3479 (calcd for C$_{23}$H$_{46}$NO$_3$, 384.3472).

Propenediester (4): colorless oil; IR (neat) 3005, 2926, 2855, 1746, 1371, 1224, 1136, 1029, 895 cm^{-1}; ^{1}H, ^{13}C, and 2D NMR data, see Table 2; HRESITOFMS *m/z* $[M + Na]^+$ 417.2978 (calcd for C$_{24}$H$_{42}$O$_4$Na, 417.2975).

Derivatization of Serinolamide (3) with (R)- and (S)-9-AMA Acids. Esters **3a** and **3b** were prepared separately by treatment of

serinolamide (**3**) (1 mg) with the corresponding (*R*)- and (*S*)-9-AMA acids (1.1 equiv) in the presence of EDC (1.1 equiv) and DMAP (catalytic) in dry CH_2Cl_2, under a N_2 atmosphere. The reaction was stirred at room temperature for 12 h. The organic layer was washed sequentially with H_2O, HCl (1 M), H_2O, $NaHCO_3$ (sat), and H_2O, then dried (Na_2SO_4) and concentrated under reduced pressure to obtain the corresponding ester. Final purification was achieved by flash column chromatography on silica gel 230−400 mesh (elution with hexanes−ethyl acetate mixtures) to yield 2.2 mg of **3a** and 1.4 mg of compound **3b**.

(R)-9-AMA ester derivative (*3a*): $[\alpha]^{25}_D$ −10.1 (*c* 1.4, CHCl$_3$); ^{1}H NMR (500 MHz, DMSO-d_6) δ 4.37 (1H, m, H-21), 4.08 (1H, dd, *J* = 7.2, 11.4 Hz, H-20a), 4.0 (1H, dd, *J* = 5.3, 11.4 Hz, H-20b), 3.08 (1H, m, H-22a), 2.98 (1H, dd, *J* = 5.5, 10.1 Hz, H-22b), 2.94 (3H, s, H-23), 2.16 (3H, s, H-19); HRESITOFMS *m/z* [M + H]$^+$ 632.4313 (calcd for $C_{40}H_{58}NO_5$, 632.4310).

(S)-9-AMA ester derivative (*3b*): $[\alpha]^{25}_D$ +10.1 (*c* 0.93, CHCl$_3$); ^{1}H NMR (500 MHz, DMSO-d_6) δ 4.46 (1H, m, H-21), 4.07 (1H, dd, *J* = 8.5, 11.6 Hz, H-20a), 3.94 (1H, dd, *J* = 4.55, 11.5 Hz, H-20b), 2.89 (3H, s, H-23), 2.88 (1H, bs, H-22a), 2.87 (1H, bs, H-22b), 1.97 (3H, s, H-19); HRESITOFMS *m/z* [M + H]$^+$ 632.4304 (calcd for $C_{40}H_{58}NO_5$, 632.4310).

CB$_1$ and CB$_2$ Receptor Binding Assays. Membranes from HEK-293 cells, stably transfected with either the human recombinant CB$_1$ receptor (B_{max} = 2.5 pmol/mg protein) or human recombinant CB$_2$ receptor (B_{max}= 4.7 pmol/mg protein), were incubated with [^{3}H]-CP-55,940 (0.14 nM/K_d = 0.18 nM and 0.084 nM/K_d = 0.31 nM, respectively, for CB$_1$ and CB$_2$ receptors) as the high-affinity ligand. This ligand was then displaced with 10 μM WIN 55212-2 as the heterologous competitor for nonspecific binding (K_i values 9.2 and 2.1 nM respectively for CB$_1$ and CB$_2$ receptors). The two compounds were tested in a preliminary screening following the procedure described by the manufacturer (Perkin-Elmer, Milano, Italy). The compound that displaced [^{3}H]CP-55,940 by more than 50% at 10 μM was further analyzed by carrying out a complete concentration−response curve (using 10, 100, 500, 1000, 2500, 10 000 nM concentrations). Displacement curves were generated by incubating test compounds for 90 min at 30 °C with [^{3}H]CP-55,940 (0.14 nM and 0.084 μM in CB$_1$ and CB$_2$ binding assays, respectively). K_i values were calculated by applying the Cheng−Prusoff equation to the IC$_{50}$ values (obtained by GraphPad) for the displacement of the bound radioligand by increasing concentrations of the test compounds. Data are means $\pm$ SEM of *n* = 3 experiments.

■ ASSOCIATED CONTENT

Ⓢ Supporting Information
^{1}H NMR, ^{13}C NMR, and 2D NMR spectra in CDCl$_3$ of compounds **3** and **4**. This material is available free of charge via the Internet at http://pubs.acs.org.

■ AUTHOR INFORMATION

Corresponding Author
*Tel: (507)-5170732. Fax: (507)-5170701. E-mail: mgutierrez@indicasat.org.pa and Tel: (858)-534-0576. Fax: (858)-534-0529. E-mail: wgerwick@ucsd.edu.

■ ACKNOWLEDGMENTS

■ REFERENCES

(1) Felder, C. C.; Glass, M. *Annu. Rev. Pharmacol. Toxicol.* **1998**, *38*, 179−200.

(2) Lambert, D. M.; Fowler, C. J. *J. Med. Chem.* **2005**, *48*, 5059−5087.

(3) Stott, C. G.; Guy, G. W. *Euphytica* **2004**, *140*, 83−93.

(4) Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mecholaum, R.; Pertwee, R. G. *Pharmacol. Rev.* **2002**, *54*, 161−202.

(5) Marzo, V. D.; Petrocellis, L. D. *Annu. Rev. Med.* **2006**, *57*, 553−574.

(6) Pacher, P.; Batkai, S.; Kunos, G. *Pharmacol. Rev.* **2006**, *58*, 389−462.

(7) Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. *Science* **1992**, *258*, 1946−1949.

(8) Gonsiorek, W.; Lunn, C.; Fan, X.; Narula, S.; Lundell, D.; Hipkin, W. *Mol. Pharmacol.* **2000**, *57*, 1045−1050.

(9) Mecholaum, R.; Shabat, S. B.; Hanus, L.; Ligumsky, M.; Kaminski, N. E.; Schatz, A. R.; Gopher, A.; Almong, A.; Martin, B. R.; Compton, D. R.; Pertwee, R. G.; Griffin, G. *Biochem. Pharmacol.* **1995**, *50*, 83−90.

(10) (a) Soderstrom, K.; Murray, T. F.; Yoo, H. D.; Ketchum, S.; Milligan, K.; Gerwick, W.; Ortega, M. J.; Salva, J. *Adv. Exp. Med. Biol.* **1997**, *433*, 73−77. (b) Pereira, A.; Pfeifer, T. A.; Grigliatti, T. A.; Andersen, R. J. *ACS Chem. Biol.* **2009**, *4*, 139−144. (c) Bisogno, T.; Melck, D.; De Petrocellis, L.; Bobrov, M. Y.; Gretskaya, N. M.; Bezuglov, V. V.; Sitachitta, N.; Gerwick, W. H.; Di Marzo, V. *Biochem. Biophys. Res. Commun.* **1998**, *248*, 515−522. (d) Han, B.; McPhail, K. L; Ligresti, A.; Di Marzo, V.; Gerwick, W. H. *J. Nat. Prod.* **2003**, *66*, 1364−1368.

(11) Gutiérrez, M.; Suyama, T. L.; Engene, N.; Wingerd, J. S.; Matainaho, T.; Gerwick, W. H. *J. Nat. Prod.* **2008**, *71*, 1099−1103.

(12) Gunstone, F. D.; Pollard, M. R.; Scrimgeour, C. M.; Vedanayagam, H. S. *Chem. Phys. Lipids* **1977**, *18*, 115−129.

(13) Freire, F.; Seco, J. M.; Quiñóa, E.; Riguera, R. *Chem. Commun.* **2007**, 1456−1458.

(14) Tidgewell, K., Clark, B. T., Gerwick, W. H. In *Comprehensive Natural Products Chemistry*, 2nd ed.; Moore, B.; Crews, P., Eds.; Pergamon Press: Oxford, UK, 2010; pp 141−188.

(15) Malfitano, A. M.; Ciaglia, E.; Gangemi, G.; Gazzerro, P.; Laezza, C.; Bifulco, M. *Expert Opin. Ther. Targets* **2011**, *15*, 297−308.

(16) Milman, G.; Maor, Y.; Abu-Lafi, S.; Horowitz, M.; Gallily, R.; Batkai, S.; Mo, F. M.; Offertaler, L.; Pacher, P.; Kunos, G.; Mechoulam, R. *Proc. Natl. Acad. Sci. U. S. A.* **2006**, *103*, 2428−2433.

(17) Colman, B.; Norman, E. *Physiol. Plant.* **1997**, *100*, 133−136.

(18) Jones, A. C.; Monroe, E. A.; Eisman, E. B.; Gerwick, L.; Sherman, D.; Gerwick, W. H. *Nat. Prod. Rep.* **2010**, *27*, 1048−1065.

(19) Geders, T. W.; Gu, L.; Mowers, J. C.; Liu, H.; Gerwick, W. H.; Hakansson, K.; Sherman, D. H.; Smith, J. L. *J. Biol. Chem.* **2007**, *282*, 35954−35963.

(20) (a) Geitler, L. In *Cyanophyceae*; Rabenhorst, L., Ed.; Akademische Verlag: Leipzig, 1932; reprint: Koeltz Scientific Books: Konigstein, 1985; pp 1060−1061. (b) Komárek, J.; Anagnostidis, K. In *Süwasserflora Von Mitteleuropa*; Büdel, B.; Gartner, G.; Krienitz, L.; Schagerl, M., Eds.; Gustav Fischer: Jena, 2005; *19/2*, pp 483−606.

(21) Mevers, E.; Liu, W. T.; Engene, N.; Mohimani, H.; Byrum, T.; Pevzner, P. A.; Dorrestein, P. C.; Spadafora, C.; Gerwick, W. H. *J. Nat. Prod.* **2011**, *74*, 928−936.

(22) Malloy, K. L.; Suyama, T. L.; Engene, N.; Debonsi, H.; Cao, Z.; Matainaho, T.; Di Marzo, V.; Spadafora, C.; Murray, T. F.; Gerwick, W. H. *J. Nat. Prod.* (submitted).